Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|NHLBI-MDS||ECOG||The National Myelodysplastic Syndromes (MDS) Study||Cancer Prevention and Control CIRB||Available to Open|
|NCIC-MA.27B||NCIC CTG||The Influence of Five Years of Adjuvant Anastrozole or Exemestane on bone Mineral Density in Postmenopausal Women with Primary Breast Cancer - A Companion Study to NCIC CTG MA.27||Adult CIRB - Late Phase Emphasis||Completed|
|ACCL1633||COG||The Effectiveness of Lactobacillus plantarum (LBP, IND #17339) In preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)||Pediatric CIRB||Available to Open|
|A011801||Alliance||The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA6191||ECOG-ACRIN||The BAMM2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|N0434 (MA.27D)||NCCTG||The Association of Breast Density Changes; Plasma Hormone Changes; and<br>Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27||Adult CIRB - Late Phase Emphasis||Available to Open|
|A191402CD||Alliance||Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men||Cancer Prevention and Control CIRB||Available to Open|
|ACNS0821||COG||Temozolomide with Irinotecan versus Temozolomide; Irinotecan plus Bevacizumab (NSC# 704865; BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood; A COG Randomized Phase II Screening Trial: A Groupwide Phase II Study||Pediatric CIRB||Available to Open|
|CCTG MA.39||NCIC CTG||Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|WF-1803CD||NCORP-Wake Forest University||Supportive Care Service Availability for Cancer Caregivers in Community Oncology Practices||Cancer Prevention and Control CIRB||Available to Open|